WMWeimin Miao

Weimin Miao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Weimin Miao has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Anders Zetterberg

    Karolinska Institutet

    1 shared publication
  • Hanzhi Liu

    State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China

    1 shared publication
  • Kun Ru

    Department of Pathology and Lab Medicine, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China

    1 shared publication
  • Li Zhang

    Department of Pediatrics, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China

    1 shared publication
  • Linping Hu

    State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China

    1 shared publication
  • Tao Cheng

    Institute of Hematology and Blood Diseases Hospital

    1 shared publication

Latest Publications

  • Open Access

    Fluorescence in situ hybridization (FISH): an increasingly demanded tool for biomarker research and personalized medicine

    by Linping Hu, Kun Ru, Li Zhang, Yuting Huang, Xiaofan Zhu, Hanzhi Liu, Anders Zetterberg, Tao Cheng, Weimin Miao

    Extensive studies of the genetic aberrations related to human diseases conducted over the last two decades have identified recurrent genomic abnormalities as potential driving factors underlying a variety of cancers. Over the time, a series of cutting-edge high-throughput genetic tests, such as microarrays and next-generation sequencing, have been developed and incorporated into routine clinical practice. Although it is a classical low-throughput cytogenetic test, fluorescence in situ hybridization (FISH) does not show signs of fading; on the contrary, it plays an increasingly important role in detecting specific biomarkers in solid and hematologic neoplasms and has therefore become an indispensable part of the rapidly developing field of personalized medicine. In this article, we have summarized the recent advances in FISH application for both de novo discovery and routine detection of chromosomal rearrangements, amplifications, and deletions that are associated with the pathogenesis of various hematopoietic and non-hematopoietic malignancies. In addition, we have reviewed the recent developments in FISH methodology as well.